$EYEN
EYENOVIA, INC.

2023 Q4 Form 10-Q Financial Statement

#000141057823001063 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q2 2023 Q1
Revenue $2.590K $0.00 $0.00
YoY Change
Cost Of Revenue $2.590K
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin 0.0%
Selling, General & Admin $3.402M $3.150M $2.940M
YoY Change 7.32% -10.88% -15.39%
% of Gross Profit
Research & Development $4.065M $2.811M $2.522M
YoY Change 78.16% -21.63% -32.07%
% of Gross Profit
Depreciation & Amortization $277.5K $124.2K $63.12K
YoY Change 253.41% 76.17% -16.32%
% of Gross Profit
Operating Expenses $7.467M $5.961M $5.459M
YoY Change 38.98% -16.3% -24.05%
Operating Profit -$7.467M -$5.961M -$5.459M
YoY Change 38.98% -16.3% -24.05%
Interest Expense -$482.0K $558.0K $454.0K
YoY Change -43.41% 263.67% 212.59%
% of Operating Profit
Other Income/Expense, Net -$18.63K $119.5K $70.99K
YoY Change -118.54% 257.89% -1103.72%
Pretax Income -$7.967M -$6.220M -$5.740M
YoY Change 30.11% -14.08% -21.79%
Income Tax
% Of Pretax Income
Net Earnings -$7.967M -$6.216M -$5.739M
YoY Change 30.11% -14.13% -21.8%
Net Earnings / Revenue -307611.58%
Basic Earnings Per Share -$0.16 -$0.15
Diluted Earnings Per Share -$0.16 -$0.16 -$0.15
COMMON SHARES
Basic Shares Outstanding 44.12M 38.00M 37.99M
Diluted Shares Outstanding 38.09M 37.41M

Balance Sheet

Concept 2023 Q4 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.85M $17.47M $18.59M
YoY Change -35.39% -18.78% -30.43%
Cash & Equivalents $14.80M $17.50M $18.50M
Short-Term Investments $0.00 $119.6K
Other Short-Term Assets $5.123M $4.734M $4.719M
YoY Change 82.02% 66.59% 157.85%
Inventory $109.8K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.71M $23.28M $24.92M
YoY Change -25.09% -9.12% -18.01%
LONG-TERM ASSETS
Property, Plant & Equipment $5.041M $3.698M $2.153M
YoY Change 289.24% 162.92% 57.1%
Goodwill
YoY Change
Intangibles $2.123M
YoY Change
Long-Term Investments $198.7K $80.87K
YoY Change -1.36% -32.06%
Other Assets $908.6K $258.0K $643.5K
YoY Change 25.1% -97.0% -92.36%
Total Long-Term Assets $8.073M $6.070M $4.385M
YoY Change 137.86% -39.26% -55.2%
TOTAL ASSETS
Total Short-Term Assets $20.71M $23.28M $24.92M
Total Long-Term Assets $8.073M $6.070M $4.385M
Total Assets $28.78M $29.35M $29.31M
YoY Change -7.27% -17.58% -27.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.753M $1.313M $1.402M
YoY Change 22.75% -51.14% -8.65%
Accrued Expenses $2.413M $1.742M $1.523M
YoY Change -9.98% -1.76% 44.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $709.9K
YoY Change
Long-Term Debt Due $5.329M $947.2K $1.219M
YoY Change 1427.49% -87.25% -84.25%
Total Short-Term Liabilities $9.530M $4.064M $4.901M
YoY Change 111.21% -66.08% -52.78%
LONG-TERM LIABILITIES
Long-Term Debt $8.957M $13.18M $7.461M
YoY Change 6.86%
Other Long-Term Liabilities $1.293M $1.584M $1.134M
YoY Change 42.42% 11608.94% 7419.56%
Total Long-Term Liabilities $10.25M $14.76M $8.595M
YoY Change 10.34% 108996.38% 56892.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.530M $4.064M $4.901M
Total Long-Term Liabilities $10.25M $14.76M $8.595M
Total Liabilities $19.78M $18.82M $13.50M
YoY Change 43.32% 56.94% 29.84%
SHAREHOLDERS EQUITY
Retained Earnings -$145.5M -$130.2M -$124.0M
YoY Change 23.1% 24.22% 27.02%
Common Stock $4.555K $3.817K $3.799K
YoY Change 24.22% 13.5% 19.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.450M $4.494M $15.91M
YoY Change
Treasury Stock Shares
Shareholders Equity $8.999M $10.52M $15.81M
YoY Change
Total Liabilities & Shareholders Equity $28.78M $29.35M $29.31M
YoY Change -7.27% -17.58% -27.07%

Cashflow Statement

Concept 2023 Q4 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$7.967M -$6.216M -$5.739M
YoY Change 30.11% -14.13% -21.8%
Depreciation, Depletion And Amortization $277.5K $124.2K $63.12K
YoY Change 253.41% 76.17% -16.32%
Cash From Operating Activities -$6.322M -$4.715M -$7.000M
YoY Change 16.97% 0.33% -14.63%
INVESTING ACTIVITIES
Capital Expenditures $145.2K $1.201M $920.9K
YoY Change 368.64% -1225.16% 427.51%
Acquisitions
YoY Change
Other Investing Activities -$2.950K -$82.81K $82.81K
YoY Change -98.95% -2.81% -350.18%
Cash From Investing Activities -$145.2K -$1.284M -$838.1K
YoY Change -53.42% 568.9% 303.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 614.3K 5.001M 3.400M
YoY Change -81.42% -1670.07% -78.27%
NET CHANGE
Cash From Operating Activities -6.322M -4.715M -7.000M
Cash From Investing Activities -145.2K -1.284M -838.1K
Cash From Financing Activities 614.3K 5.001M 3.400M
Net Change In Cash -5.853M -998.2K -4.397M
YoY Change 142.86% -80.84% -160.61%
FREE CASH FLOW
Cash From Operating Activities -$6.322M -$4.715M -$7.000M
Capital Expenditures $145.2K $1.201M $920.9K
Free Cash Flow -$6.467M -$5.916M -$7.921M
YoY Change 18.98% 28.82% -5.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001682639
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37991746
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36668980
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38365
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1178401
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
295 Madison Avenue, Suite 2400
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
NEW YORK
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
CY2023Q1 dei City Area Code
CityAreaCode
833
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
393-6684
CY2023Q1 dei Trading Symbol
TradingSymbol
EYEN
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
3730278
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38002965
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18466322
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22863520
CY2023Q1 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
3352645
CY2022Q4 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
2284931
CY2023Q1 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
973677
CY2022Q4 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
1183786
CY2023Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
119550
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
119550
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2011884
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1190719
CY2023Q1 us-gaap Assets Current
AssetsCurrent
24924078
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27642506
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2152861
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1295115
CY2023Q1 eyen Security Deposits
SecurityDeposits
80874
CY2022Q4 eyen Security Deposits
SecurityDeposits
80874
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1508158
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1291592
CY2023Q1 eyen Equipment Deposits
EquipmentDeposits
643513
CY2022Q4 eyen Equipment Deposits
EquipmentDeposits
726326
CY2023Q1 us-gaap Assets
Assets
29309484
CY2022Q4 us-gaap Assets
Assets
31036413
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1402076
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1428283
CY2023Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
637189
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1747191
CY2023Q1 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
460143
CY2022Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
503076
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
472901
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
484882
CY2023Q1 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
123480
CY2022Q4 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
33885
CY2023Q1 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
1218963
CY2022Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
174448
CY2023Q1 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
123480
CY2022Q4 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
33885
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
709853
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
174448
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4901125
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4512328
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1133948
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
907644
CY2023Q1 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
648889
CY2022Q4 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
813229
CY2022Q4 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
4190938
CY2023Q1 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
648889
CY2022Q4 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
813229
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3730278
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4190938
CY2023Q1 us-gaap Liabilities
Liabilities
13495629
CY2022Q4 us-gaap Liabilities
Liabilities
13801848
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37991746
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36668980
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
3799
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3667
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139779885
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135461361
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123969829
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118230463
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15813855
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29309484
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31036413
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2521950
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3712584
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2936886
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3474965
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5458836
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
7187549
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5458836
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7187549
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70993
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7073
CY2023Q1 us-gaap Interest Expense
InterestExpense
454003
CY2022Q1 us-gaap Interest Expense
InterestExpense
145237
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
102480
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
194
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7339665
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q1 eyen Prepaid Patent Expense
PrepaidPatentExpense
61569
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37410587
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37410587
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30008194
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30008194
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3499592
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
819064
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15813855
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20466615
CY2022Q1 eyen Stock Issued During Period Value New Issues Two
StockIssuedDuringPeriodValueNewIssuesTwo
14897908
CY2022Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
860365
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908987
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7339665
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29794210
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7339665
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
819064
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
908987
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63119
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
75432
CY2023Q1 eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
149490
CY2022Q1 eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
26215
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
133907
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
89718
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
212025
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
907774
CY2023Q1 eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-210109
CY2022Q1 eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-440756
CY2023Q1 eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1067714
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26207
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-79340
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1110002
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-868224
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-42933
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-441012
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-136150
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-89492
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6958708
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8184399
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
920865
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
174567
CY2023Q1 eyen Vendor Deposits For Property Plant And Equipment
VendorDepositsForPropertyPlantAndEquipment
-82813
CY2022Q1 eyen Vendor Deposits For Property Plant And Equipment
VendorDepositsForPropertyPlantAndEquipment
33095
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-838052
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-207662
CY2022Q1 eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
14981299
CY2023Q1 eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
3607827
CY2022Q1 eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
860365
CY2023Q1 eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
108235
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
100030
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
111793
CY2022Q1 eyen Payments For Repurchase Of Public Offering
PaymentsForRepurchaseOfPublicOffering
83391
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3399562
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15646480
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4397198
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7254419
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22863520
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27336850
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18466322
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34591269
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18466322
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26716269
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
7875000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18466322
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34591269
CY2023Q1 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
304512
CY2022Q1 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
95585
CY2023Q1 eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
609140
CY2022Q1 eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
675331
CY2022Q1 eyen Recognition Of Right Of Use Asset For Lease Liability Upon Adoption Of Accounting Standard Update
RecognitionOfRightOfUseAssetForLeaseLiabilityUponAdoptionOfAccountingStandardUpdate
618906
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
350473
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
79181
CY2023Q1 eyen Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
2
CY2022Q1 eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
2
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18500000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5700000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7300000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7000000.0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8200000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
201082
CY2023Q1 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
645566
CY2022Q4 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
660891
CY2023Q1 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
176935
CY2022Q4 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
87982
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain prior period balances have been reclassified in order to conform to current period presentation. These reclassifications have no effect on previously reported results of operations or loss per share.</p>
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
15910834
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
2055488
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
22613520
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7339665
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5739366
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7339665
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
37380976
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
28032758
CY2022Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1870130
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29611
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
105306
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37410587
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30008194
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q1 eyen Prepaid Conference Expenses
PrepaidConferenceExpenses
132026
CY2022Q4 eyen Prepaid Conference Expenses
PrepaidConferenceExpenses
97743
CY2023Q1 eyen Prepaid Director Fees Current
PrepaidDirectorFeesCurrent
106250
CY2022Q4 eyen Prepaid Director Fees Current
PrepaidDirectorFeesCurrent
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11698522
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12847777
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
803486
CY2022Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
38796
CY2023Q1 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2022Q4 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
74959
CY2023Q1 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
13006
CY2022Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2521
CY2023Q1 us-gaap Other Assets
OtherAssets
54296
CY2022Q4 us-gaap Other Assets
OtherAssets
26745
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2011884
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1190719
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
330500
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1447643
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
306689
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
299548
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
637189
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1747191
CY2023Q1 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
325886
CY2022Q4 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
320000
CY2023Q1 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
59090
CY2022Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
35524
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24537
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4385
CY2023Q1 eyen Credit Card Payable
CreditCardPayable
22286
CY2022Q4 eyen Credit Card Payable
CreditCardPayable
50639
CY2023Q1 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
15244
CY2022Q4 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
0
CY2023Q1 eyen Accrued Franchise Tax
AccruedFranchiseTax
13100
CY2022Q4 eyen Accrued Franchise Tax
AccruedFranchiseTax
0
CY2023Q1 eyen Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
0
CY2022Q4 eyen Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
92528
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
460143
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
503076
CY2023Q1 us-gaap Notes Payable
NotesPayable
10934110
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1544738
CY2023Q1 eyen Notes Payable Net Of Debt Discount Total
NotesPayableNetOfDebtDiscountTotal
9389372
CY2022Q4 us-gaap Notes Payable
NotesPayable
10425000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1694228
CY2022Q4 eyen Notes Payable Net Of Debt Discount Total
NotesPayableNetOfDebtDiscountTotal
8730772
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
2175776
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
246960
CY2023Q1 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
1928816
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
416666
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
67770
CY2022Q4 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
348896
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
8758334
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1297778
CY2023Q1 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
7460556
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
10008334
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1626458
CY2022Q4 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
8381876
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
100030
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
145237
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
136150
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
350473
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
482350000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
480984000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
429992000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
308839000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
214619000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1916784000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
309935000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1606849000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
472901000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1133948000
CY2023Q1 eyen Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
3500000
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1299947
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
819064
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
908987
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
172800
CY2022Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
1.80
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
22222
CY2023Q1 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeited In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice
1.80
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
150578
CY2023Q1 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
1.80
CY2023Q1 eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber
29611
CY2023Q1 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice
3.68
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q1 eyen Number Of Shares Issued Upon Exercise Of Stock Options
NumberOfSharesIssuedUponExerciseOfStockOptions
19530
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73334
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5460099
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3933774
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3228544
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2019Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2019Q2 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04
CY2023Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
78969
CY2022Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
86099

Files In Submission

Name View Source Status
eyen-20230331_cal.xml Edgar Link unprocessable
eyen-20230331_def.xml Edgar Link unprocessable
0001410578-23-001063-index-headers.html Edgar Link pending
0001410578-23-001063-index.html Edgar Link pending
0001410578-23-001063.txt Edgar Link pending
0001410578-23-001063-xbrl.zip Edgar Link pending
eyen-20230331.xsd Edgar Link pending
eyen-20230331x10q.htm Edgar Link pending
eyen-20230331xex31d1.htm Edgar Link pending
eyen-20230331xex31d2.htm Edgar Link pending
eyen-20230331xex32d1.htm Edgar Link pending
eyen-20230331xex32d2.htm Edgar Link pending
eyen-20230331x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eyen-20230331_lab.xml Edgar Link unprocessable
eyen-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable